Curasight A/S announced that the investigator-initiated phase II study using uPAR-PET in brain cancer has now completed the inclusion of patients. The investigator-initiated trial testing 68Ga-NOTA-AE105 uPAR-PET/MR in patients with gliomas (most common primary brain cancers) aimed to collect data on 30 patients out of a total of 35 patients recruited to the trial. This number has now been reached and the first data analysis can begin according to the primary investigator.

The trial, being carried out at Rigshospitalet in Copenhagen, is designed to investigate the diagnostic performance of uPAR-PET in brain cancer. First data from the study is expected to be published during H2 2022.